For the quarter ending 2025-09-30, SPRY made $32,501K in revenue. -$51,112K in net income. Net profit margin of -157.26%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 32,501 | 15,717 | 7,973 | 2,068 |
| Cost of goods sold (including related party amounts of 2,046, 0, 3,400, and 0, respectively) | 8,191 | 4,984 | 1,094 | 112 |
| Research and development (including related party amounts of 559, 406, 1,804, and 1,651, respectively) | 2,751 | 4,035 | 2,952 | 4,423 |
| Selling, general and administrative (including related party amounts of 123, 129, 354, and 337, respectively) | 74,751 | 54,312 | 41,104 | 19,281 |
| Total operating expenses | 85,693 | 63,331 | 45,150 | 23,816 |
| Loss from operations | -53,192 | -47,614 | -37,177 | -21,748 |
| Other income (expense), net (including related party amounts of , 0, , and 0, respectively) | 2,041 | 2,731 | 3,237 | 2,620 |
| Net loss | -51,151 | -44,883 | -33,940 | -19,128 |
| Change in unrealized gains and losses on available-for-sale securities | 39 | -118 | -148 | 484 |
| Comprehensive loss | -51,112 | -45,001 | -34,088 | -18,644 |
| Earnings per share, basic, total | -0.52 | -0.46 | -0.35 | -0.2 |
| Earnings per share, diluted, total | -0.52 | -0.46 | -0.35 | -0.2 |
| Weighted average number of shares outstanding, basic, total | 98,807,600 | 98,361,771 | 98,060,636 | 97,032,331 |
| Weighted average number of shares outstanding, diluted, total | 98,807,600 | 98,361,771 | 98,060,636 | 97,032,331 |
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)